Govt plans to shut down two pharma PSUs

The government has decided to close two pharma public sector undertakings and disinvest the other three, Parliament was informed.

“The Department of Pharmaceuticals has five public sector undertakings (PSUs). Out of the five PSUs, the government has taken a decision to close two pharma PSUs, namely:

Indian Drugs & Pharmaceuticals Ltd (IDPL) and
Rajasthan Drugs & Pharmaceuticals Ltd (RDPL),

said D V Sadananda Gowda, Minister of Chemicals and Fertilisers, in response to a question in the Lok Sabha.

The government has also decided to strategically disinvest the other three:

Hindustan Antibiotics Ltd (HAL),
Bengal Chemicals & Pharmaceuticals Ltd (BCPL), and
Karnataka Antibiotics & Pharmaceutical Ltd (KAPL),

The government has offered voluntary retirement benefits to all employees of IDPL and RDPL, Gowda said.

“However, the Committee of Ministers constituted on September 9, 2019, will take necessary decisions pertaining to closure/strategic sale of the pharma public sector undertakings, including the sale of assets and clearance of outstanding liabilities,” he added.

Related Posts

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy, the online medical platform emphasizes the importance of early prevention and regular health screenings to reduce the risk of diabetes. By encouraging individuals to undergo timely blood sugar tests,…

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

India’s pharmaceutical exporters have been offered a fresh business opportunity to expand their presence in Saudi Arabia, with Riyadh-based Al Hobail Medical Company seeking Indian manufacturing partners for the registration…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

UP expands food, drug testing capacity across all 18 divisions

UP expands food, drug testing capacity across all 18 divisions

Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi

Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi